Valuation: Compass Therapeutics, Inc.

Market Cap 154M 137M 128M 117M 220M 14.83B 222M 1.55B 600M 7.58B 579M 567M 24.33B P/E 2026 *
-1.73x
P/E 2027 * -1.53x
Enterprise Value 4.28M 3.8M 3.55M 3.24M 6.1M 412M 6.16M 42.97M 16.65M 210M 16.07M 15.73M 675M EV / Sales 2026 *
-
EV / Sales 2027 * 3.27x
Free-Float
87.54%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 65 28/05/2024
Director of Finance/CFO 54 09/12/2024
Chief Tech/Sci/R&D Officer 50 01/01/2026
Director TitleAgeSince
Director/Board Member 65 01/01/2014
Director/Board Member 64 01/01/2015
Chairman 61 01/01/2015
Change 5-day change 1-year change 3-year change Capi.($)
-10.80%+32.67% - - 154M
+4.16%+3.04%+49.37%+94.17% 74.16B
-3.11%-3.53%+21.92%+74.60% 57.39B
+0.89%-0.63%+4.28%+34.51% 47.64B
+0.36%+0.81%+352.17%+689.61% 44.29B
-0.96%-4.50%+26.36%+33.18% 42.5B
-0.20%-0.77%+3.74%+100.60% 40.71B
-0.54%+2.93%+9.31%+50.41% 30.97B
-2.68%+2.92%+29.63%+19.50% 28.53B
+0.05%-1.64%-7.28%-14.06% 24.34B
Average -1.28%-0.59%+54.39%+120.28% 43.39B
Weighted average by Cap. +0.12%-0.84%+58.77%+129.91%

Financials

2026 *2027 *
Net sales - 6.51M 5.79M 5.4M 4.92M 9.28M 626M 9.37M 65.35M 25.32M 320M 24.45M 23.92M 1.03B
Net income -93.27M -82.87M -77.34M -70.49M -133M -8.97B -134M -936M -363M -4.58B -350M -343M -14.71B -112M -99.26M -92.64M -84.44M -159M -10.74B -161M -1.12B -434M -5.49B -419M -410M -17.62B
Net Debt -150M -133M -124M -113M -214M -14.42B -216M -1.51B -583M -7.37B -563M -551M -23.66B -133M -118M -110M -101M -190M -12.79B -191M -1.33B -517M -6.54B -499M -489M -20.98B
Logo Compass Therapeutics, Inc.
Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is developing proprietary antibody-based therapeutics to treat multiple human diseases. Its pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. Its lead product candidate, tovecimig, is a bispecific antibody targeting Delta-like ligand 4 (DLL4), a ligand of Notch-1, and vascular endothelial growth factor A (VEGF-A). Its second program, CTX-471, is an agonistic antibody targeting a member of the tumor necrosis factor receptor superfamily member 9 (TNFRSF9), also known as CD-137, a co-stimulatory receptor which is mostly expressed on activated, but not on resting T-cells and NK cells. Its third program, CTX-8371, is a bispecific antibody targeting the programmed cell death protein-1 (PD-1), an inhibitory immune checkpoint receptor, and its ligand PD-L1, two validated immune-oncology targets.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
0.8567USD
Average target price
5.455USD
Spread / Average Target
+536.69%

Quarterly revenue - Rate of surprise